Skip to main content

Advertisement

SpringerLink
Log in

The transcriptional activity of WT1 gene promoter and enhancer in cell lines with diverse tissue origin

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

In this study, tissue-specific transcriptional activity of WT1 promoter and enhancer was investigated in a hope to design gene therapy strategy based on the transcriptional regulatory elements of WT1 gene. WT1 promoter and/or enhancer were ligated into pEGFP-1 to construct recombinant vectors with EGFP gene as a reporter and analyzed using Flow cytometry. The results showed that pEWP containingWT1 promoter induced the highest EGFP expression in ECV304 at 16.54 ± 2.45 times, mildly higher in MCF-7 and SHG44 at 9.46 ± 1.10 and 7.29 ± 0.73 times, and in K562 cell line at 2.93 ± 0.27 times, compared to that of pEGFP-1. However, pEWPA, with WT1 enhancer inserted at Afl II site, increased basal transcription levels of the WT1 promoter in HT-29, SHI-1 and K562 cells by 4.81, 3.06 and 1.01-fold, respectively. pEWPD inserted at NotI and pEWPE inserted at BamI had no ability to increase the transcriptional activity of WT1 promoter. Moreover, reporter gene silenced was observed in transfected host cells by flow cytometryt and real-time PCR. These results suggested that transcriptional activities of WT1 promoter in the recombinant vector seemed not correlated to the constitutional expression level of endogenous WT1 gene. The WT1 enhancer could promote the transcriptional activities of WT1 promoter in some of the cell lines regardless of the hematopoietic tissue origin. The inserted site of enhancer in vector influenced the transcriptional activity of promoter and the extent of reporter gene silencing exerted the influence on the analysis of transcriptional activity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60:509–20.

    Article  CAS  PubMed  Google Scholar 

  2. Gessler M, Poustka A, Cavenee W, et al. Homozygous deletion in Wilms tumours of a gene identified by chromosome jumping. Nature. 1990;343:774–8.

    Article  CAS  PubMed  Google Scholar 

  3. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms’ tumor gene is involved in genitourinary development. Nature. 1990;346:194–7.

    Article  CAS  PubMed  Google Scholar 

  4. Haber DA, Buckler AJ. WT1: a novel tumor suppressor gene inactivated in Wilm’s tumor. New Biol. 1992;4:97–106.

    CAS  PubMed  Google Scholar 

  5. Brown KW, Watson JE, Poirier V, et al. Inactivation of the remaining allele of the wt1 gene in a Wilms’ tumour from a WAGR patient. Oncogene. 1992;7:763–8.

    CAS  PubMed  Google Scholar 

  6. Gao L, Bellantuono I, Elsasser A, et al. Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000;95:2198–203.

    CAS  PubMed  Google Scholar 

  7. Baird PN, Simmons PJ. Expression of the Wilms tumor gene (WT1) in normal hemopoiesis. Exp Hematol. 1997;25:312–20.

    CAS  PubMed  Google Scholar 

  8. Im HJ, Kong G, Lee H. Expression of Wilms tumor gene (WT1) in children with acute leukemia. Pediatr Hematol Oncol. 1999;16:109–18.

    Article  CAS  PubMed  Google Scholar 

  9. Tamaki H, Ogawa H, Ohyashiki K, et al. The Wilms’ tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia. 1999;13:393–9.

    Article  CAS  PubMed  Google Scholar 

  10. Sugiyama H. Wilms tumor gene (WT1) as a new marker for the detection of minimal residual disease in leukemia. Leuk Lymphoma. 1998;30:55–61.

    Article  CAS  PubMed  Google Scholar 

  11. Chen ZX. The possible role and application of WT1 in human leukemia. Int J Hematol. 2001;73:39–46.

    Article  CAS  PubMed  Google Scholar 

  12. Oji Y, Suzuki T, Nakano Y, et al. Overexpression of the Wilms’ tumor gene WT1 in primary astrocytic tumors. Cancer Sci. 2004;95:822–7.

    Article  CAS  PubMed  Google Scholar 

  13. Oka Y, Udaka K, Tsuboi A, et al. Cancer immunotherapy targeting Wilms’ tumor gene WT1 product. J Immunol. 2000;164:1873–80.

    Article  CAS  PubMed  Google Scholar 

  14. Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood. 2000;95:286–93.

    CAS  PubMed  Google Scholar 

  15. Gaiger A, Reese V, Disis ML, et al. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia. Blood. 2000;96:1480–9.

    CAS  PubMed  Google Scholar 

  16. Fraizer GC, Wu YJ, Hewitt SM, et al. Transcriptional regulation of the human Wilms’ tumor gene (WT1). Cell type-specific enhancer and promiscuous promoter. J Biol Chem. 1994;269:8892–900.

    CAS  PubMed  Google Scholar 

  17. Zhang XH, Xing GX, Fraizer GC, Saunders GF. Transaction of an intronic hematopoietic -specific enhancer of human Wilms’ Tumor 1 gene by GATA-1 and c-Myb. J Biol Chem. 1997;272:29272–80.

    Article  CAS  PubMed  Google Scholar 

  18. Hosen N, Yanagihara M, Nakazawa T, et al. Identification of a gene element essential for leukemia-specific expression of transgenes. Leukemia. 2004;18:415–9.

    Article  CAS  PubMed  Google Scholar 

  19. Gu WY, Chen ZX, Hu SY, et al. Changes in expression of WT1 isoforms during induced differentiation of the NB4 cell line. Haematologica. 2005;90:403–5.

    CAS  PubMed  Google Scholar 

  20. Kar-Roy A, Wei D, Michael N, et al. Green fluorescence protein as a transcriptional reporter for the long terminal repeats of the human immunodeficiency virus type 1. J Virol Methods. 2000;84:127–38.

    Article  CAS  PubMed  Google Scholar 

  21. Srinivasa Reddy MS, Dinkins RD, Collins GB. Gene silencing in transgenic soybean plants transformed via particle bombardment. Plant Cell Rep. 2003;21:676–83.

    Google Scholar 

  22. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res. 1986;46:5276–81.

    CAS  PubMed  Google Scholar 

  23. Balzarini J, Bohman C, De Clercq E. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2. J Biol Chem. 1993;268:6332–7.

    CAS  PubMed  Google Scholar 

  24. Ilsley DD, Lee SH, Miller WH, et al. Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action. Biochemistry. 1995;34:2504–10.

    Article  CAS  PubMed  Google Scholar 

  25. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 2000;60:3989–99.

    CAS  PubMed  Google Scholar 

  26. Glienke W, Maute L, Koehl U, et al. Effective treatment of leukemic cell lines with wt1 siRNA. Leukemia. 2007;21:2164–70.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We acknowledge Dr. Gail C. Fraizer for generous provision of the plasmids. This study is supported by the grant #39770306 from the National Natural Science Foundation of China and the grant #06KJB320101 from Natural Science Basic Research of higher learning institution of Jiangsu Province.

Author information

Authors and Affiliations

  1. Doctor’s Degree of Medicine, Department of Hematology and Oncology, Children’s Hospital of Soochow University, 215003, Suzhou, China

    Shaoyan Hu

  2. Doctor’s Degree of Medicine, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, 215006, Suzhou, China

    Zixing Chen

  3. Doctor’s Degree of Medicine, Department of Hematology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of SooChow University, 213003, Changzhou, China

    Weiying Gu

  4. The First Affiliated Hospital of Soochow University, 215006, Suzhou, China

    Ruihua Chen, Ye Zhao & Jiannong Cen

  5. No. 96, Shizi Street, 215006, Suzhou, China

    Zixing Chen

Authors
  1. Shaoyan Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zixing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weiying Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ruihua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ye Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jiannong Cen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zixing Chen.

About this article

Cite this article

Hu, S., Chen, Z., Gu, W. et al. The transcriptional activity of WT1 gene promoter and enhancer in cell lines with diverse tissue origin. Int J Hematol 87, 498–506 (2008). https://doi.org/10.1007/s12185-008-0090-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-008-0090-7

Keywords

Search

Navigation